In a clinically relevant model in murine, adoptive transfer of anti-CEA CAR-engineered T-cells was able to specifically and efficiently reduce the size of pancreatic tumors below the limit of detection in all mice and give continuing tumor eradication in 67% of mice [60]. This evidence concerns the gene CEACAM5 and neoplasm.